A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI).

Trial Profile

A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil
  • Indications Colorectal cancer; Liver metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Mar 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 11 Mar 2012 Actual end date (Mar 2007) added as reported by University Hospital Medical Information Network - Japan.
    • 08 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top